Parkinson's Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020

Feb. 29, 2012 - PRLog -- In 2011, the global Parkinson’s Disease (PD) therapeutics market, which includes the key markets of the US, Japan, Germany, the UK, France, Italy, Spain, Brazil, China, India and Russia was estimated to be worth $2,992m. During the period 2002-2011, the global PD therapeutics market grew at a Compound Annual Growth Rate (CAGR) of 5.8%. GlobalData analysis shows that the market size was primarily driven by two key parameters: the increase in PD prevalence due to the increase in the aging population in the 11 key markets and the increasing cost of therapy.

In 2011, the market registered a decline in the market valuations due to the entry of generics for Mirapex (pramipexole) and higher preference for generic ropinirole. The market declined from $3,499m in 2010 to $2,992m in 2011. The US was leading PD therapeutics market, with an estimated value of $1,046m in 2011 and a market share of 35%. Japan was the second biggest market, with an estimated value of $542m and an 18.1% market share, followed by Germany with a market share of 15.6%.

The global PD therapeutics market is primarily served by levodopa, dopamine agonists, Monoamine Oxidase Inhibitors (MAO-BI) and Catechol-O-Methyltransferase (COMT) inhibitors. The market is dominated by branded products such as Boehringer Ingelheim’s Mirapex/Mirapexin / Sifrol / Mirapex ER / Mirapexin ER (pramipexole), GlaxoSmithKline’s (GSK) Requip/Requip XL (ropinirole), Orion / Novartis’ Stalevo/Comtan (carbidopa/levodopa/entacapone) and Teva/Lundbeck’s Azilect/Agilect (rasagiline). In addition, a large number of generics are also available in this market.

In 2011, the top three drugs in the G7 markets (the US, Japan, Germany, the UK, Spain, France, and Italy) were Stalevo/Comtan, Mirapex, and Azilect with annual sales of $688.2m, $567.8m and $323.5m respectively.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....


The global PD therapeutics market is expected to grow at a modest CAGR of 2.2% and is forecast to reach $3,650m by 2020. This modest growth rate is due to the patent expiries of major drugs, the subsequent entry of generics and the weak, late-stage developmental pipeline. The major drugs, which are expected go off patent during this period are Azilect, Comtan, Stalevo, Tasmar, Mirapex ER and Requip XL, of which the impact is expected to be partially adjusted by the introduction of new drugs such as IPX 066, preladenant and safinamide during 2011-2020

GlobalData has released its pharma report, “Parkinson’s Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the global Parkinson’s disease Therapeutics therapeutics market. The report provides comprehensive information on Parkinson’sDisease Therapeutics, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global Parkinson’s Disease Therapeutics therapeutics market. It analyses the treatment usage patterns in the global Parkinson’s Disease Therapeutics therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global Parkinson’s Disease Therapeutics sector. It quantifies the unmet need in the global Parkinson’s Disease Therapeutics therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players. This report is built using data and information sourced from proprietary databases, primary and secondary research.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Park...


Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.